Results From the Phase II TROPION-Lung05 Study by Jacob Sands et al.
A recent paper by Jacob Sands, Medical Oncologist at Dana-Farber Cancer Institute, was mentioned by Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center in Athens, on X:
Authors: Jacob Sands, Myung-Ju Ahn, Aaron Lisberg, Rachel Chiaverelli, Luis Paz-Ares et al.
“Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study | Journal of Clinical Oncology.”
More posts featuring Giannis Mountzios.
Giannis Mountzios, M.D., is the Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center in Athens, Greece.
He is a member of the Publishing Working Group of ESMO and has co-edited several key oncology texts, including the Handbook of Oncological Emergencies, the Guide for AYA with Cancer, and the Handbook of Supportive and Palliative Care.
Dr. Mountzios has published over 130 articles in peer-reviewed journals, including The Lancet, Cell, Nature Reviews Clinical Oncology, Journal of Clinical Oncology, Cancer Discovery, Annals of Oncology, Journal of Thoracic Oncology, and Clinical Cancer Research.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023